Daily Stock Analysis, APRI, Apricus Biosciences Inc, priceseries

Apricus Biosciences Inc. Daily Stock Analysis
Stock Information
Open
2.40
Close
2.25
High
2.40
Low
2.25
Previous Close
2.29
Daily Price Gain
-0.04
YTD High
4.07
YTD High Date
Jan 18, 2017
YTD Low
1.19
YTD Low Date
Jan 9, 2017
YTD Price Change
0.88
YTD Gain
64.23%
52 Week High
7.50
52 Week High Date
Mar 28, 2016
52 Week Low
1.10
52 Week Low Date
Dec 12, 2016
52 Week Price Change
-4.85
52 Week Gain
-68.31%
Recent priceSeries Trade Signals

These are sample algorithmic trades based on actual market data.

Trade Type
Entry Date
Entry Price
Exit Date
Exit Price
Trade Hold Time
Gain
Trade Record
LONG
Jan 2. 2015
12.00
Jan 13. 2015
13.23
7 Trading Days
10.23%
Link
LONG
Feb 3. 2015
13.90
Mar 9. 2015
23.62
23 Trading Days
69.96%
Link
LONG
Aug 28. 2015
13.50
Sep 14. 2015
15.74
10 Trading Days
16.63%
Link
LONG
Jun 22. 2016
4.80
Jun 23. 2016
5.40
1 Trading Days
12.50%
Link
LONG
Sep 12. 2016
3.40
Sep 23. 2016
3.60
9 Trading Days
5.88%
Link
LONG
Jan 17. 2017
1.51
Feb 28. 2017
2.99
29 Trading Days
97.91%
Link
Company Information
Stock Symbol
APRI
Exchange
NasdaqCM
Company URL
http://www.apricusbio.com
Company Phone
(858) 222-8041
CEO
Richard W. Pascoe
Headquarters
California
Business Address
11975 EL CAMINO REAL,, SUITE 300, SAN DIEGO,, CA 92130
Sector
Equity
Industry Category
Drugs
Industry Group
Drug Manufacturers - Other
CIK
0001017491
About

Apricus Biosciences, Inc., a biopharmaceutical company, focuses on the development and commercialization of products and product candidates in the areas of urology and rheumatology.

Description

Apricus Biosciences, Inc., a biopharmaceutical company, focuses on the development and commercialization of products and product candidates in the areas of urology and rheumatology. Its lead product is Vitaros, a topically-applied cream formulation of alprostadil used for the treatment of erectile dysfunction. The company's marketing partners for Vitaros include Laboratoires Majorelle, Bracco S.p.A., Hexal AG (Sandoz), Takeda Pharmaceuticals International GmbH, Recordati Ireland Ltd. (Recordati S.p.A.), Ferring International Center S.A. (Ferring Pharmaceuticals), Mylan NV, Neopharm Scientific Limited, Elis Pharmaceuticals Limited, and Global Harvest Pharmaceutical Corporation. It also develops second-generation Vitaros, a proprietary stabilized dosage formulation that is expected to be stored at room temperature conditions; and Fispemifene, a tissue-specific selective estrogen receptor modulator that is in Phase IIb clinical trial to treat secondary hypogonadism, lower urinary tract symptoms, and chronic prostatitis in men. In addition, the company plans to initiate a Phase IIb trial for RayVa to treat Raynaud's phenomenon associated with scleroderma; and develops Femprox, a product candidate for the treatment of female sexual interest/arousal disorder. It operates in Latin America, Europe, and internationally. The company was formerly known as NexMed, Inc. and changed its name to Apricus Biosciences, Inc. in September 2010. Apricus Biosciences, Inc. was founded in 1987 and is headquartered in San Diego, California.